Atorvastatin in factorial with omega-3 fatty acid risk reduction in diabetes

Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN76737502

Enrollment

1000

Registered

2004-09-14

Start date

2004-11-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine Diabetes

Interventions

Placebo-controlled double-blind, 2 x 2 factorial randomisation - it is a one year treatment trial of 1000 participants, 250 randomised to each receive either: 1. Atorvastatin (Lipitor 20mg/day) and c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or above 2. Have had Type 2 diabetes for at least 3 months 3. Not known to have had a cardiovascular event 4. Have provided written informed consent 5. In UK general practice

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026